https://charts.traderzeitung.de/phases/US4622601007
string(1520) "{"isin":"US4622601007","name":"Iovance Biotherapeutics Inc","stock_id_xnas":7874178,"stock_id_xnys":null,"generated_at":"2026-07-18 01:44:00","days":[{"date":"2026-07-15","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":3.94,"close_at":"2026-07-15 15:28:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.755,"close_at":"2026-07-15 21:59:00","complete":true,"perf_pct":20.6853},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":4.7,"close_at":"2026-07-15 22:47:00","complete":true,"perf_pct":-1.1567}]},{"date":"2026-07-16","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":4.65,"close_at":"2026-07-16 14:09:00","complete":true,"perf_pct":-1.0638},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.655,"close_at":"2026-07-16 21:59:00","complete":true,"perf_pct":0.1075},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":4.66,"close_at":"2026-07-16 23:59:00","complete":true,"perf_pct":0.1074}]},{"date":"2026-07-17","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":4.56,"close_at":"2026-07-17 15:26:00","complete":true,"perf_pct":-2.1459},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.995,"close_at":"2026-07-17 21:59:00","complete":true,"perf_pct":9.5395},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":5.04,"close_at":"2026-07-17 23:49:00","complete":true,"perf_pct":0.9009}]}]}"
Iovance Biotherapeutics Aktie News & Nachrichten
Trading-Room

Iovance Biotherapeutics Aktie News & Nachrichten

[WKN: A2DT49 | Symbol: IOVA]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
Iovance Biotherapeutics Chart

Artikel aus der Redaktion der Trader-Zeitung

Iovance Biotherapeutics

Iovance: Zelltherapiepionier skaliert endlich – jetzt rückt der Lungenkrebsmarkt in den Fokus

Enttäuschte Erwartungen ließen den Kurs der Iovance-Aktie im Zeitraum März 2024 bis Anfang Mai 2025...

  • ‹
  • 1
  • ›
Iovance Biotherapeutics Nachrichtenticker öffnen
MT Newswires 18.06.2026 22:57 Uhr

Iovance Biotherapeutics reicht gemischtes Shelf-Registrierungsdokument ein

04:56 PM EDT, 06/18/2026 (MT Newswires) -- Iovance Biotherapeutics (IOVA) reichte am Donnerstag eine Registrierungserklärung für den potenziellen, gel

MT Newswires 03.06.2026 23:13 Uhr

Iovance Biotherapeutics erhält bedingte australische Zulassung für Amtagvi bei fortgeschrittenem Melanom

05:12 PM EDT, 06/03/2026 (MT Newswires) -- Iovance Biotherapeutics (IOVA) teilte mit, dass Australiens Therapeutic Goods Administration eine bedingte

MT Newswires 01.06.2026 14:56 Uhr

Iovance Biotherapeutics erhält US-FDA-Zulassung zum Beginn der IOV-5001-Studie bei soliden Tumoren

08:55 AM EDT, 06/01/2026 (MT Newswires) -- Iovance Biotherapeutics (IOVA) teilte am Montag mit, dass es die Genehmigung der US Food and Drug Administr